Antibody validation: a view from the mountains
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Validation of antibodies and other protein binders is a subject of pressing concern for the research community and one which is uppermost in the minds of all who use antibodies as research and diagnostic reagents. Assessing an antibody’s fitness for purpose includes accurate ascertainment of its target specificity and suitability for the envisaged task. Moreover, standardised procedures are essential to guarantee sample quality in testing procedures. The problem of defining precise standards for antibody validation has engendered much debate in recent publications and meetings, but gradually a consensus is emerging. At the 8th Alpbach Affinity Proteomics workshop (March 2017), a panel of leaders in the antibody field discussed suggestions which could bring this complex but essential issue a step nearer to a resolution. ‘Alpbach recommendations’ for best practice include tailoring binder validation processes according to the intended applications and promoting greater transparency in publications and in the information available from commercial antibody developers/providers. A single approach will not fit all applications and end users must ensure that the reported validation holds for their specific use, highlighting the need for adequate training in the fundamentals of antibody characterisation and validation across the user community.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1×
“antibodies in research can also be seen as part of a larger drive to enhance rigour, reliability and transparency of biomedical research in general [12-18].”
Policy: NIH plans to enhance reproducibility
Collins, F. S., & Tabak, L. A. (2014) · Nature · doi:10.1038/505612a · Cited by 1,247 · cited 1×
“Issues around antibodies in research can also be seen as part of a larger drive to enhance rigour, reliability and transparency of biomedical research in general [12-18].”
BackgroundA call for transparent reporting to optimize the predictive value of preclinical research
Landis, S. C., Amara, S. G., Asadullah, K., Austin, C. P., Blumenstein, R., Bradley, E. W., Crystal, R. G., Darnell, R. B., Ferrante, R. J., Fillit, H., et al. (2012) · Nature · doi:10.1038/nature11556 · Cited by 1,196
Micheva, K. D., & Smith, S. J. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.014 · Cited by 787
Reproducibility: Standardize antibodies used in research
Bradbury, A., & Plückthun, A. (2015) · Nature · doi:10.1038/518027a · Cited by 647 · cited 1×
“A major area of recent discussion has been the benefits, over standard pAb and mAb reagents, of using antibodies and other binders produced by recombinant technologies, or by conventional means and then converted into recombinant form [45,46].”
BackgroundFixing problems with cell lines
Lorsch, J. R., Collins, F. S., & Lippincott-Schwartz, J. (2014) · Science · doi:10.1126/science.1259110 · Cited by 179
Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific
Jensen, B. C., Swigart, P. M., & Simpson, P. C. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-008-0368-6 · Cited by 176
Bradbury, A. R. M., Trinklein, N. D., Thie, H., Wilkinson, I. C., Tandon, A. K., Anderson, S., Bladen, C. L., Jones, B., Aldred, S. F., Bestagno, M., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1445456 · Cited by 121
Self-citationBandrowski, A. E., & Martone, M. E. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.030 · Cited by 75
Improving the reliability of peer-reviewed publications: We are all in it together
Bustin, S. A., & Nolan, T. (2016) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2015.11.002 · Cited by 22 · cited 1×
“Issues around antibodies in research can also be seen as part of a larger drive to enhance rigour, reliability and transparency of biomedical research in general [12-18].”
Background
Cited by
Laflamme, C., McKeever, P. M., Kumar, R., Schwartz, J., Kolahdouzan, M., Chen, C. X., You, Z., Benaliouad, F., Gileadi, O., McBride, H. M., et al. (2019) · eLife · doi:10.7554/elife.48363 · Cited by 155
Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Antibody characterization is critical to enhance reproducibility in biomedical research
Kahn, R. A., Virk, H., Laflamme, C., Houston, D. W., Polinski, N. K., Meijers, R., Levey, A. I., Saper, C. B., Errington, T. M., Turn, R. E., et al. (2024) · eLife · doi:10.7554/elife.100211 · Cited by 32
Self-citation
Metadata
- Authors
- Taussig, M. J., Fonseca, C., & Trimmer, J. S.
- Venue
- New Biotechnology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 45
- Pages
- 1-8
- ISSN
- 1871-6784 (ISSN-L)
- OpenAlex
- W2887716776
- Cited by
- 53
- References
- 10
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody validation: a view from the mountains. https://app.cochat.ai/papers/10.1016/j.nbt.2018.08.002
- The paper
- Taussig, M. J., Fonseca, C., & Trimmer, J. S. (2018). Antibody validation: a view from the mountains. New Biotechnology. https://doi.org/10.1016/j.nbt.2018.08.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.